Affymax (AFFY) Says OMONTYS Approved for CKD Patients in U.S.

Affymax, Inc. (Nasdaq: AFFY) and Takeda Pharmaceutical Company Limited, announced that OMONTYS (peginesatide) Injection is now available only for use in treating anemia due to chronic kidney disease (CKD) in adult patients on dialysis. OMONTYS is the only once-monthly erythropoiesis-stimulating agent (ESA) for anemia available to the dialysis patient population in the United States. OMONTYS is co-marketed by Affymax and Takeda Pharmaceuticals U.S.A. (TPUSA) and distributed by TPUSA.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• CoVolt Power files for proposed IPO
• BIGG Digital Assets to rename as Surge Digital, consolidate shares